๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical effects of organophosphorus cholinesterase inhibitors

โœ Scribed by Frederick R. Sidell

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
355 KB
Volume
14
Category
Article
ISSN
0260-437X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Nerve agents, highly toxic organophosphorus cholinesterase inhibitors, inhibit acetylcholinesterase and cause an accumulation of acetylcholine. Clinical effects depend on the route and amount of exposure and include miosis, bronchoconstriction, excessive secretions, vomiting, seizures, and cessation of respiratory and cardiac activity. Eye effects include miosis, engorgement of ocular vessels, pain, and a decrease in light sensitivity. Therapy consists of atropine, a cholinesterase reactivator (pralidoxime), and ventilation as needed.

This paper results from work carried out under US Government auspices and is not subject to copyright.

๐Ÿ“œ SIMILAR VOLUMES

Ten years of cholinesterase inhibitors
Ten years of cholinesterase inhibitors
โœ Joanne Rodda; Zuzana Walker ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 141 KB

## Abstract In this editorial we have summarised ten years of evidence relating to the use of cholinesterase inhibitors in Alzheimer's and other dementias. We have presented this evidence in the context of the evolution of public and professional awareness of dementia and its management and prescri

Weak inhibitors protect cholinesterases
Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine
โœ G. A. Petroianu; K. Arafat; A. Schmitt; M. Y. Hasan ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 190 KB

## Abstract Metoclopramide (MCP) is a dopamine receptor antagonist and serotonin receptor agonist widely used as an antiemetic and gastric prokinetic drug. In addition MCP is a weak and reversible inhibitor of cholinesterases. We have shown that MCP has a cholinesterase protective effect against in

Weak inhibitors protect cholinesterases
Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride
โœ G. A. Petroianu; M. Y. Hasan; K. Arafat; S. M. Nurulain; A. Schmitt ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 161 KB

Weak and reversible inhibitors of cholinesterases, when administered before potent organophosphorus inhibitors (pretreatment), have the ability, to a certain extent, to protect enzymes from inhibition. Such a protective effect was demonstrated in vitro for metoclopramide and ranitidine. The putative

Clinical predictors of response to acety
Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle
โœ S. Pakrasi; E. B. Mukaetova-Ladinska; I. G. McKeith; J. T. O'Brien ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB

## Abstract ## Background Acetyl Cholinesterase Inhibitors (AChEIs) have been in clinical use for the past five years in the UK for the symptomatic treatment of Alzheimer's disease (AD). There are few data on the patterns and predictors of response to AChEI therapy in routine clinical practice. We